Researchers have discovered a new way to treat hepatocellular carcinoma (HCC) the most common type of liver cancer, and the third leading cause of cancer death worldwide.
The Centenary Institute led study revealed an encouraging treatment strategy involving the use of a new drug called Blockmir CD5-2, combined with a drug called programmed cell death protein 1 antibody (anti-PD1 antibody). This combination proved effective in reducing liver tumour size in mice.
Lead author of the study, Dr Ken Liu, a researcher in the Centenary Institute’s Centre for Cancer Innovations said the discovery was exciting and had the potential to be a viable treatment for advanced liver cancer.
"The synergistic effect of the drugs Blockmir CD5-2 and anti-PD1 antibody significantly reduced the size of liver tumours in mice in our study. We believe that this dual-drug approach enhances the immune system, rendering it more efficient in combatting cancer cells and reducing tumours,” said Dr Liu.
Dr Liu explained that liver tumours often have abnormal blood vessels and low oxygen levels, creating an environment that suppresses the immune system and the body’s ability to fight cancer.
“Blockmir CD5-2 addresses this issue by promoting the health of tumour blood vessels through the activation of a protein called VE-Cadherin. This results in improved blood supply and oxygen levels within the tumours," said Dr Liu.
"The enhanced blood vessel conditions within the tumours means that more cancer-targeting immune cells, specifically cytotoxic T cells, can infiltrate the tumour and effectively combat the disease,” he said.
The researchers said that use of the anti-PD1 antibody was also a crucial component of the innovative treatment approach, helping the immune system fight cancer more effectively by blocking a protein that hinders the immune response.
Senior study authors, Professor Jennifer Gamble from the Centenary Institute’s Centre for Healthy Ageing and Professor Geoff McCaughan from the Centenary Institute’s Centre for Cancer Innovations said that current effective treatment options for liver cancer were limited and that the new therapeutic approach held tremendous potential for effectively treating such a challenging disease.
The research was published in the journal Frontiers in Immunology.
[ENDS]
Publication:
Novel miRNA-based drug CD5-2 reduces liver tumour growth in diethylnitrosamine (DEN)-treated mice by normalising tumour vasculature and altering immune infiltrate. https://www.frontiersin.org/articles/10.3389/fimmu.2023.1245708/
Images:
Dr Ken Liu
https://drive.google.com/file/d/1a7Cu9bN78Jd0Cx5wBJ3D3SeGP1DDu3zT/view?usp=sharing
https://drive.google.com/file/d/14-9953HTzCKocPXbaFe0YvOlaZPKG35O/view?usp=sharing
About us:
About the Centenary Institute
The Centenary Institute is a world-leading independent medical research institute, closely affiliated to the University of Sydney and the Royal Prince Alfred Hospital. Our research focuses on three key areas: cancer, inflammation and cardiovascular disease. Our strength lies in uncovering disease mechanisms and applying this knowledge to improve diagnostics and treatments for patients.
For more information about the Centenary Institute, visit centenary.org.au
Contact details:
For all media and interview enquiries, please contact
Tony Crawshaw, Media and Communications Manager, Centenary Institute on 0402 770 403 or email: t.crawshaw@centenary.org.au
